Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information. It grants free access to its research in PubMed Central and other repositories for unrestricted reuse. A study assessed the association between in-hospital anticoagulation (AC) and survival in hospitalized COVID-19 patients. Among 2,773 patients, 28% received treatment-dose AC. Those treated had lower in-hospital mortality (22.5%) and longer survival (21 days) compared to those without AC (22.8% and 14 days). Patients on AC were more likely to require mechanical ventilation. AC was associated with increased baseline coagulation markers, but not in ventilated patients. In ventilated patients, AC was linked to lower mortality (29.1% vs. 62.7%). Longer AC duration reduced mortality risk (adjusted HR 0.86 per day). Bleeding events were more common in AC-treated patients, though not significantly higher. The study suggests AC may improve outcomes but risks bleeding, requiring individualized use. Another study found acute myocardial injury at admission was linked to higher all-cause mortality in COVID-19 patients. Among 179 enrolled, 116 had troponin I tests. Nonsurvivors were older, had more comorbidities, and higher myocardial injury rates. Multivariable analysis showed acute myocardial injury significantly increased mortality risk. These findings highlight the importance of monitoring cardiac function in COVID-19 patients. Both studies emphasize the need for further research to confirm AC benefits.Elsevier established a free COVID-19 resource center in January 2020, offering English and Mandarin information. It grants free access to its research in PubMed Central and other repositories for unrestricted reuse. A study assessed the association between in-hospital anticoagulation (AC) and survival in hospitalized COVID-19 patients. Among 2,773 patients, 28% received treatment-dose AC. Those treated had lower in-hospital mortality (22.5%) and longer survival (21 days) compared to those without AC (22.8% and 14 days). Patients on AC were more likely to require mechanical ventilation. AC was associated with increased baseline coagulation markers, but not in ventilated patients. In ventilated patients, AC was linked to lower mortality (29.1% vs. 62.7%). Longer AC duration reduced mortality risk (adjusted HR 0.86 per day). Bleeding events were more common in AC-treated patients, though not significantly higher. The study suggests AC may improve outcomes but risks bleeding, requiring individualized use. Another study found acute myocardial injury at admission was linked to higher all-cause mortality in COVID-19 patients. Among 179 enrolled, 116 had troponin I tests. Nonsurvivors were older, had more comorbidities, and higher myocardial injury rates. Multivariable analysis showed acute myocardial injury significantly increased mortality risk. These findings highlight the importance of monitoring cardiac function in COVID-19 patients. Both studies emphasize the need for further research to confirm AC benefits.